Get the latest information on Ozempic lawsuits and semaglutide legal developments directly from drug injury lawyers involved in Ozempic class-action cases.
Federal court mandates gastric emptying studies for all Ozempic gastroparesis lawsuits. If you have a confirmed diagnosis through scintigraphy, breath test, or WMC, learn how this August 2025 ruling affects your compensation claim.
A recent Harvard Medical School study has revealed a potential link between a rare but serious eye condition and semaglutide, the active ingredient in popular weight loss and diabetes medications such as Ozempic, Rybelsus, Wegovy, and Mounjaro.
Judge Karen Spencer Marston’s Case Management Order No. 14, issued July 14, 2024, introduces key changes to the Ozempic MDL. It establishes direct filing in the Eastern District of Pennsylvania and streamlines service for Novo Nordisk defendants. This update affects Ozempic, Wegovy, Rybelsus, and Victoza cases, simplifying the process for plaintiffs while preserving defendants’ rights.
The Honorable Karen Spencer Marston has issued an order rescheduling the Science Day for the Ozempic, Wegovy, Rybelsus, and Mounjaro multidistrict litigation (MDL). Initially set for July 14, 2024, the new date is September 4, 2024. This rescheduling is a significant development in the legal proceedings, potentially affecting numerous plaintiffs who allege various injuries from these GLP-1 receptor agonist (GLP-1 RA) medications.
GLP-1 RA litigation preps for Science Day where experts will discuss the science and the reported side effects related to these diabetes and weight loss drugs.
Heated exchanges set the tone leading up to April’s Ozempic status conference. Parties debated liability, advocated for PFSs & challenged defendant strategies.
Ozempic Litigation Update: Details from the April 18, 2024, Status Conference Overview of the Status Conference On April 18, 2024, Judge Gene E.K. Pratter presided
Overview of the Ozempic Litigation The federal judge overseeing the Ozempic litigation, Hon. Gene E.K. Pratter, conducted the first status conference on March 14, 2024,
MDL Court Advances GLP-1 RAS Litigation with Initial Case Management Conference In a significant step forward for the ongoing GLP-1 RAS litigation, Judge Gene E.
This guide aims to simplify your search for the best weight loss drug lawyer for your injury claims against Ozempic, Mounjaro, Wegovy & Rybelsus.
Explore eligibility for filing an Ozempic lawsuit focused on severe side effects like gastroparesis and intestinal blockages. Understand the criteria and legal options available for affected patients and their families seeking compensation.
Aiming for efficient litigation for claimants, all federal GLP-1 RA cases, including Ozempic & Wegovy gallbladder lawsuits, are now consolidated in MDL 3094.
